Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan

Xenobiotica

Volumn 29, Issue 8, 1999, Pages 847-857

  Wild, M J ^a   McKillop, D ^a   Butters, C J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CLORGYLINE; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; ZOLMITRIPTAN;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER MICROSOME; MALE;

CIMETIDINE; CLORGYLINE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; HUMANS; ISOENZYMES; KETOCONAZOLE; LIVER; MALE; MICROSOMES, LIVER; OMEPRAZOLE; OXAZOLES; OXAZOLIDINONES; RECOMBINANT PROTEINS; SEROTONIN AGONISTS; THEOPHYLLINE; TRYPTAMINES;

EID: 0032878034     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982599238290     Document Type: Article

References (28)

1. BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica, 25, 261-270.
2. BELANGER, P. M., LALANDE, M. and ATITSE-GBEASSOR, A., 1983, Differential properties of the microsomal deamination and hydroxylation reactions. Research Communications in Chemical Pathology and Pharmacology, 40, 429-441.
3. DIXON, R., FRENCH, S., KEMP, J., SELLERS, M. and YATES, R., 1998, The metabolism of zolmitriptan. Effects of an inducer and an inhibitor of cytochrome P450 on its pharmacokinetics in healthy volunteers. Clinical Drug Investigation, 15, 515-522.
4. DIXON, C. M., PARK, G. R. and TARBIT, M. H., 1994, Characterisation of the enzyme responsible for the metabolism of sumatripan in human liver. Biochemical Pharmacology, 47, 1253-1257.
5. DIXON, R. and WARRANDER, A., 1997, The clinical pharmacokinetics of zolmitriptan. Cephalalgia, 17 (suppl. 18), 15-20.
6. FORRESTER, L. M., HENDERSON, C. J., GLANCEY, M. J., BACK, D. J., PARK, B. K., BALL, S. E., KITTERINGHAM, N. R., MCLAREN, A. W., MILES, J. S., SKETT, P. and WOLF, C. R., 1992, Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochemical Journal, 281, 359-368.
7. 1D agonist 311C90. Headache, 34, 394-399.
8. GUENGERICH, F. P., 1997, Role of cytochrome P450 enzymes in drug-drug interactions. Advances in Pharmacology, 43, 7-35.
9. HOUSTON, J. B., 1994, Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology, 47, 1469-1479.
10. IWATSUBO, T., HIROTA, N., OOIE, T., SUZUKI, H., SHIMADA, N., CHIBA, K., ISHIZAKl, T., GREEN, C. E., TYSON, C. A. and SUGIYAMA, Y., 1997, Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology and Therapeutics, 73, 147-171.
11. KALGUTKAR, A. S., CASTAGNOLI, N. and TESTA, B., 1995, Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism. Medicinal Research Reviews, 15, 325-388.
12. KAUBE, H., HOSKIN, K. and GOADSBY, P. J., 1993, Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. British Journal of Pharmacology, 109, 788-792.
13. KNODELL, R, G., BROWN, D. G., GWOZDE, G. P., BRIAN, W. R. and GUENGERICH, F. P., 1991, Differential inhibition of individual human liver cytochromes P450 by cimetidine. Gastroenterology, 101, 1680-1691.
14. LIVINGSTON, M. G. and LIVINGSTON, H. M., 1996, Monoamine oxidase inhibitors. An update on drug interactions. Drug Safety, 14, 219-227.
15. MCKILLOP, D., 1985, Effects of phenobarbitone and β-naphthoflavone on hepatic microsomal drug metabolising enzymes of the male beagle dog. Biochemical Pharmacology, 34, 3137-3142.
16. MCKILLOP, D., WILD, M. J., BUTTERS, C. J. and SIMCOCK, C., 1998, Effects of propofol on human microsomal cytochrome P450 activities. Xenobiotica, 28, 845-853.
17. NEWTON, D. J., WANG, R. W. and LU, A. Y. H., 1995, Cytochrome P450 inhibitors - evaluation of the specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
18. PECK, R. W., SEABER, E. J., DIXON, R., GILLOTIN, C. G., WEATHERLEY, B. C., LAYTON, G. and POSNER, J., 1997, The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). British Journal of Clinical Pharmacology, 44, 595-599.
19. PRESKORN, S. H., 1997, Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clinical Pharmacokinetics, 32 (suppl. 1), 1-21.
20. REESE, J. A. and BYARD, J. L., 1981, Isolation and culture of adult rat hepatocytes from liver biopsies. In Vitro, 17, 935-941.
21. ROBERTS, R. K., GRICE, J., WOOD, L., PETROFF, V. and McGUFFIE, C., 1981, Cimetidine impairs the elimination of theophylline and antipyrine. Gastroenterology, 81, 19-21.
22. RODRIGUES, A. D., 1994. Use of in vitro human metabolism studies in drug development: an industrial perspective. Biochemical Pharmacology, 48, 2147-2156.
23. ROLAN, P., 1997, Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia, 17 (suppl. 18), 21-27.
24. 1B/1D agonist: an overview of efficacy. Cephalalgia, 17 (suppl. 18), 28-40.
25. SEABER, E., ON, N., DIXON, R. M., GIBBENS, M., LEAVENS, W. J., LIPTROT, J., CHITTICK, G., POSNER, J., ROLAN, P. E. and PECK, R. W., 1997, The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). British Journal of Clinical Pharmacology, 43, 579-587.
26. SEABER, E., ON, N., PHILLIPS, S., CHURCHUS, R., POSNER, J. and ROLAN P., 1996, The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. British Journal of Clinical Pharmacology, 41, 141-147.
27. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 270, 414-423.
28. SMITH, D. A., CLEARY, E. W., WATKINS, S., HUFFMAN, C. S, and POLVINO, W. J., 1998, Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics, 36, 301-305.